Transplantation-associated microangiopathy (TAM) is one of the major complications after hematopoietic stem cell transplantation, with a mortality rate of 60-90%, 1 and has some clinical and pathological features similar to clinical syndromes of thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. Clinical manifestations include hemolytic anemia with schistocytes on peripheral blood smears, thrombocytopenia, elevated levels of serum lactate dehydrogenase, and decreased levels of haptoglobin. The etiology of TAM remains to be fully elucidated, but is thought to involve injury to endothelial cells by toxic insults, such as cytotoxic chemotherapy, calcineurin inhibitors, infection and graft-versus-host disease, resulting in a hypercoagulable state and exaggerated cytokine production. 1 Although classic idiopathic thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome are successfully treated using plasma exchange, TAM is not. It has recently been reported that rituximab, an anti-CD20 antibody, might be useful for the treatment of both TAM and classic thrombotic thrombocytopenic purpura in which ADAMTS13, a metalloprotease cleaving multimeric von Willebrand factor, is profoundly decreased due to autoantibody formation. 2 Recombinant human soluble thrombomodulin (rTM) comprises the active, extracellular domain of thrombomodulin, and inactivates coagulation by binding to thrombin. 3 In addition, thrombin-rTM complex activates protein C to produce activated protein C, which inactivates factors VIIIa and Va in the presence of protein S, thereby inhibiting further thrombin formation. 3 A recent phase III trial comparing the efficacy and safety of rTM to those of low-dose heparin showed that rTM significantly improved disseminated intravascular coagulation (DIC) associated with hematological malignancies or infections. 4 Use of rTM for the treatment of DIC has recently been approved in Japan.
We describe herein a case of hematopoietic stem cell transplantation complicated by TAM and sepsis, that was successfully treated using rTM and teicoplanin. A 24-yearold woman presented with diffuse large B cell lymphoma refractory to both CHOP (cyclophosphamide, adriamycin, vincristine and prednisone) with rituximab and high-dose chemotherapy followed by auto-peripheral blood stem cell transplantation and involved-field radiation therapy. She subsequently received peripheral blood stem cell transplantation from an HLA-matched sibling. The conditioning regimen comprised fludarabine and melphalan. Graftversus-host disease prophylaxis included cyclosporine A and short-term methotrexate. On post-transplant day 22, she experienced a high fever with chills and blood culture revealed methicillin-resistant Staphylococcus hominis. Teicoplanin administration was therefore initiated. At that time, acute, grade II graft-versus-host disease of the skin developed and was managed with topical prednisone ointment. On post-transplant day 23, platelet count suddenly dropped to 5 Â 10 3 per ml and became transfusion dependent. She also developed hemolytic anemia in association with appearance of red blood cell fragmentation on peripheral blood smears. Serum levels of lactate dehydrogenase jumped to 860 U/l and haptoglobin levels decreased to 6 mg/100 ml. Direct and indirect Coombs tests yielded negative results, leading to a diagnosis of TAM according to the International Working Group criteria.
1 Cyclosporine A was discontinued and rituximab (375 kg/m 2 ) was administered. Furthermore, rTM (380 U/kg for 6 days) was initiated because coagulation tests indicated a state of DIC, as evidenced by elevated levels of fibrinogen degraded product (13.1 mg/ml) and D-dimer (6.46 mg/ml), and prolonged prothrombin time (13.0 s). The informed consent with Kochi University institutional review board approval was obtained from the patient before initiation of treatment using rTM. Surprisingly, results of coagulation tests promptly began to normalize and both levels of hemoglobin and platelet counts increased in parallel with the disappearance of fragmented red blood cells (Figure 1) .
We later noticed that ADAMTS13 activity had remained 460%, and the autoantibody against ADAMTS13 might not be produced though it has not been tested. Rituximab was thus considered unlikely to have had a function in alleviation of TAM in this case. In addition, after completion of treatment with rTM, fibrinogen degraded product levels were apparently decreased and prothrombin time was normalized. These observations suggest that rTM probably had central roles in alleviating TAM.
Bone marrow examination revealed no infiltration of lymphoma cells, and physical examination found that lymphoma was under control after hematopoietic stem cell transplantation, excluding the possibility that lymphoma caused TAM and DIC in this case. Although the activity of ADAMTS13 was shown to be decreased less than 45% in severe sepsis, 5 it is likely that methicillin-resistant S. hominis caused sepsis that triggered TAM in this case. It is possible that teicoplanin also contributed to improvement of TAM.
Recent studies have found that rTM possesses antiinflammatory activity through both protein C-dependent and -independent pathways. The N-terminal domain of TM binds to and inactivates high-mobility group box 1 protein, 6 a proinflammatory cytokine that stimulates the production of inflammatory cytokines, such as interleukin 6 and tumor necrosis factor a through toll-like receptor 4 and receptor for advanced glycation end product. In addition, a phase III clinical trial has shown that rTM increases levels of anti-thrombin III and decreases levels of plasminogen activator inhibitor 1 in patients with DIC. 4 rTM could possess the ability to protect endothelial cells from injury. We have recently used rTM to successfully treat two patients with hepatic sinusoidal obstructive syndrome complicated by hematopoietic stem cell transplantation (Ikezoe T, unpublished data). Similar to TAM, hepatic sinusoidal obstructive syndrome is also thought to be caused by endothelial cell damage, further supporting our hypothesis that rTM could protect endothelial cells from injury. Thus, rTM could alleviate TAM through several different mechanisms. Further studies are clearly required to confirm our hypothesis.
Although our experience is limited to one patient, administration of rTM may offer an effective treatment for coagulation abnormalities including TAM. Ohno Letter to the Editor
